Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Misses on EPS, Stock Down 5.03%

Aurinia Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a decline in the stock price by 5.03%. The lack of revenue figures and guidance may raise concerns among investors about the company's financial outlook. The absence of management commentary further adds uncertainty regarding future performance.